{"transactions":[{"id":723991,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:34:03.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001456849-26-000002","document":"form4-06292026_080659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000145684926000002/form4-06292026_080659.xml","form_type":"4"}},{"id":813364,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-08T01:09:02.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":44500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2027."}],"balance_after":44500,"derivative":{"exercise_price":7.61,"expiration_date":"2036-04-01","underlying":"Common Stock","underlying_shares":44500},"source":{"system":"sec-edgar","filing":"0001104659-26-040570","document":"tm2611350-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465926040570/tm2611350-4_4seq1.xml","form_type":"4"}},{"id":972584,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-11T21:30:22.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":false,"shares":3169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares underlying this stock option vested on January 21, 2016."}],"balance_after":0,"derivative":{"exercise_price":1.75,"expiration_date":"2026-01-21","underlying":"Common Stock","underlying_shares":3169},"source":{"system":"sec-edgar","filing":"0001104659-25-120332","document":"tm2533265-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465925120332/tm2533265-1_4seq1.xml","form_type":"4"}},{"id":972583,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-11T21:30:22.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":3169,"price":10.4,"value":32957.6,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-120332","document":"tm2533265-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465925120332/tm2533265-1_4seq1.xml","form_type":"4"}},{"id":972582,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-11T21:30:22.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":3169,"price":1.75,"value":5545.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person exercised the option due to the upcoming expiration date of the option."}],"balance_after":3169,"source":{"system":"sec-edgar","filing":"0001104659-25-120332","document":"tm2533265-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465925120332/tm2533265-1_4seq1.xml","form_type":"4"}},{"id":997691,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2025-11-17T21:30:09.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option."}],"balance_after":0,"derivative":{"exercise_price":0.93,"expiration_date":"2035-02-12","underlying":"Common Shares","underlying_shares":33390},"source":{"system":"sec-edgar","filing":"0001456849-25-000005","document":"form4-11172025_041105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000145684925000005/form4-11172025_041105.xml","form_type":"4"}},{"id":997690,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-17T21:30:09.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the \" Purchase Agreement\") in exchange for (i) $1.04 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001456849-25-000005","document":"form4-11172025_041105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000145684925000005/form4-11172025_041105.xml","form_type":"4"}},{"id":1061786,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-20T01:59:37.000Z","date":"2025-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000306","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000161071725000306/form4.xml","form_type":"4"}},{"id":1104938,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T21:40:59.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000246","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000161071725000246/form4.xml","form_type":"4"}},{"id":1113454,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:23:13.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017050","document":"form4-06122025_100609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017050/form4-06122025_100609.xml","form_type":"4"}},{"id":1179418,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-04T00:03:31.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2026."}],"balance_after":32000,"derivative":{"exercise_price":8.4,"expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-25-031831","document":"tm2511407-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465925031831/tm2511407-7_4seq1.xml","form_type":"4"}},{"id":1263642,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares (Right to Buy)","published_at":"2025-02-19T01:15:13.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":33390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date."}],"balance_after":33390,"derivative":{"exercise_price":0.93,"expiration_date":"2035-02-12","underlying":"Common Shares","underlying_shares":33390},"source":{"system":"sec-edgar","filing":"0001415889-25-004527","document":"form4-02182025_080210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000141588925004527/form4-02182025_080210.xml","form_type":"4"}},{"id":1488467,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:50:48.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015819","document":"form4-06062024_090644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015819/form4-06062024_090644.xml","form_type":"4"}},{"id":1488319,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:31:25.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":11871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the \"Vesting Commencement Date\") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11871,"derivative":{"exercise_price":19.17,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":11871},"source":{"system":"sec-edgar","filing":"0001610717-24-000303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000161071724000303/form4.xml","form_type":"4"}},{"id":1539885,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-17T20:15:56.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":49265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from April 15, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":49265,"derivative":{"exercise_price":19.89,"expiration_date":"2034-04-14","underlying":"Common Stock","underlying_shares":49265},"source":{"system":"sec-edgar","filing":"0001610717-24-000209","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000161071724000209/form4.xml","form_type":"4"}},{"id":1549368,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T00:01:38.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2025."}],"balance_after":32000,"derivative":{"exercise_price":7.73,"expiration_date":"2034-04-01","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-24-043255","document":"tm2410652-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465924043255/tm2410652-8_4seq1.xml","form_type":"4"}},{"id":1889099,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:06:25.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008241","document":"form4-05182023_010514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008241/form4-05182023_010514.xml","form_type":"4"}},{"id":1927921,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-05T00:03:56.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":25200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2024."}],"balance_after":25200,"derivative":{"exercise_price":17.66,"expiration_date":"2033-04-01","underlying":"Common Stock","underlying_shares":25200},"source":{"system":"sec-edgar","filing":"0001104659-23-041733","document":"tm2311410-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465923041733/tm2311410-13_4seq1.xml","form_type":"4"}},{"id":2234210,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T23:05:12.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-22-006517","document":"form4-06132022_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922006517/form4-06132022_040601.xml","form_type":"4"}},{"id":2304250,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-05T20:12:32.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2023."}],"balance_after":16500,"derivative":{"exercise_price":18.26,"expiration_date":"2032-04-01","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001104659-22-042758","document":"tm2211665-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465922042758/tm2211665-9_4seq1.xml","form_type":"4"}},{"id":2658870,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T22:13:17.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":15000,"derivative":{"exercise_price":12.55,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-084241","document":"tm2120371-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921084241/tm2120371-2_4seq1.xml","form_type":"4"}},{"id":2745441,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:39:43.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":4.14,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-027413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027413/doc4.xml","form_type":"4"}},{"id":2745440,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:39:43.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":6.09,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-027413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027413/doc4.xml","form_type":"4"}},{"id":2745439,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:39:43.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":17.27,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-027413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027413/doc4.xml","form_type":"4"}},{"id":2745438,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:39:43.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":29.8,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-027413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027413/doc4.xml","form_type":"4"}},{"id":2745437,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:39:43.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":37.99,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-027413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027413/doc4.xml","form_type":"4"}},{"id":2757628,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-06T00:11:28.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2022."}],"balance_after":16500,"derivative":{"exercise_price":31.58,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001104659-21-046718","document":"tm2112099d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465921046718/tm2112099d1_4.xml","form_type":"4"}},{"id":2899356,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T21:59:54.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":29842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in thirty-six (36) equal monthly installments following the Grant Date."}],"balance_after":29842,"derivative":{"exercise_price":27.45,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":29842},"source":{"system":"sec-edgar","filing":"0000899243-21-002963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002963/doc4.xml","form_type":"4"}},{"id":2951654,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-10T00:48:13.000Z","date":"2020-12-07","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vested on January 21, 2016."}],"balance_after":3169,"derivative":{"exercise_price":1.75,"expiration_date":"2026-01-21","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-133812","document":"tm2038101-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465920133812/tm2038101-1_4seq1.xml","form_type":"4"}},{"id":2951653,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T00:48:13.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":1802,"price":47.04,"value":84766.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.85 to $47.21. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-133812","document":"tm2038101-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465920133812/tm2038101-1_4seq1.xml","form_type":"4"}},{"id":2951652,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T00:48:13.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":13523,"price":46.22,"value":625033.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.85 to $46.84. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1802,"source":{"system":"sec-edgar","filing":"0001104659-20-133812","document":"tm2038101-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465920133812/tm2038101-1_4seq1.xml","form_type":"4"}},{"id":2951651,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T00:48:13.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":24675,"price":45.09,"value":1112595.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.82. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15325,"source":{"system":"sec-edgar","filing":"0001104659-20-133812","document":"tm2038101-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465920133812/tm2038101-1_4seq1.xml","form_type":"4"}},{"id":2951650,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T00:48:13.000Z","date":"2020-12-07","kind":"exercise","acquired":true,"shares":40000,"price":1.75,"value":70000.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001104659-20-133812","document":"tm2038101-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465920133812/tm2038101-1_4seq1.xml","form_type":"4"}},{"id":3147499,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-15T17:46:35.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) May 14, 2021 or (ii) the day before the 2021 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":20000,"derivative":{"exercise_price":4.14,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-029829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120029829/doc4.xml","form_type":"4"}},{"id":3186464,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-02T20:31:33.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2021."}],"balance_after":16500,"derivative":{"exercise_price":9.78,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001104659-20-042500","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465920042500/a4.xml","form_type":"4"}},{"id":3492933,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-12T18:11:40.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":15000,"derivative":{"exercise_price":6.09,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-036497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119036497/doc4.xml","form_type":"4"}},{"id":3564618,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-04-03T21:33:08.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2020."}],"balance_after":13500,"derivative":{"exercise_price":15.5,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001104659-19-019720","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465919019720/a4.xml","form_type":"4"}},{"id":3860809,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-26T21:25:32.000Z","date":"2018-07-24","kind":"grant","acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 24 equal monthly installments thereafter."}],"balance_after":13500,"derivative":{"exercise_price":15,"expiration_date":"2028-07-19","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001104659-18-047458","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1456849/000110465918047458/a4.xml","form_type":"4"}},{"id":3934999,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-14T19:47:32.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) May 10, 2019 or (ii) the day before the 2019 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":10000,"derivative":{"exercise_price":17.27,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-030064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118030064/doc4.xml","form_type":"4"}},{"id":4322940,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-12T16:22:35.000Z","date":"2017-05-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":10000,"derivative":{"exercise_price":29.8,"expiration_date":"2027-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-031943","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117031943/doc4.xml","form_type":"4"}}]}